Introduction Aging shifts bone remodeling toward a negative balance between bone formation and resorption,causing bone loss and increased fracture risk.Anti-resorptive agents are commonly used to inhibit bone resorpti...Introduction Aging shifts bone remodeling toward a negative balance between bone formation and resorption,causing bone loss and increased fracture risk.Anti-resorptive agents are commonly used to inhibit bone resorption and stabilize bone mass.While they are effective to prevent further bone loss,there is also a great need for anabolic agents which can reverse bone deterioration and regain lost skeletal integrity.PTH,the only FDA-approved anabolic treatment for osteoporosis,greatly stimulates bone formation.Combined therapy of anti-resorptive treatments,such as alendronate(ALN),and PTH have been proposed and are expected to further increase bone mass.However,studies show conflicting results regarding the effectiveness展开更多
基金supported by McCabe pilot award and the Penn Center for Musculoskeletal Disorders(NIH/NIAMS P30AR050950)
文摘Introduction Aging shifts bone remodeling toward a negative balance between bone formation and resorption,causing bone loss and increased fracture risk.Anti-resorptive agents are commonly used to inhibit bone resorption and stabilize bone mass.While they are effective to prevent further bone loss,there is also a great need for anabolic agents which can reverse bone deterioration and regain lost skeletal integrity.PTH,the only FDA-approved anabolic treatment for osteoporosis,greatly stimulates bone formation.Combined therapy of anti-resorptive treatments,such as alendronate(ALN),and PTH have been proposed and are expected to further increase bone mass.However,studies show conflicting results regarding the effectiveness
